Clinical Trials · NCT00896532
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 419
- Start date
- Jun 2009
- Locations
- See registry
- Primary endpoint
- Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine